Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614845 | 0.88 | KCNH2 (0.40) | KCNH2 | |
| SCHEMBL1615222 | 0.88 | EGFR (0.40) | — | |
| SCHEMBL1615631 | 0.87 | THRB (0.36) | THRBDHODHMAPK14MAPK13KCNH2 | |
| SCHEMBL1615792 | 0.84 | PIK3CG (0.32) | THRBDHODHMAPK14MAPK13 | |
| SCHEMBL1615984 | 0.81 | EGFR (0.36) | THRBDHODHMAPK14MAPK13ALK | |
| SCHEMBL1615058 | 0.79 | APP (0.34) | THRBDHODHMAPK14MAPK13ALK | |
| SCHEMBL1615082 | 0.78 | THRB (0.32) | THRBDHODHMAPK14MAPK13 | |
| SCHEMBL13787038 | 0.73 | EGFR (0.43) | — | |
| SCHEMBL13787050 | 0.73 | MAP2K1 (0.44) | KCNH2 | |
| SCHEMBL1616005 | 0.72 | PIK3CG (0.34) | THRBDHODHMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2690101-B1 | 5-Anilinoimidazopyridines and Methods of Use | GENENTECH INC (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2690101-B1 | 5-Anilinoimidazopyridines and Methods of Use | GENENTECH INC (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2690101-A1 | 5-Anilinoimidazopyridines and Methods of Use | Genentech, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690101-A1 | 5-Anilinoimidazopyridines and Methods of Use | Genentech, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2222675-B1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH INC (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2222675-B1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120309765-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8288408-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2222675-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | Genentech, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009085983-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309765-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | THRB 3487/4885DHODH 177/4885MAPK14 1615/4885 |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | THRB 3487/4885DHODH 177/4885MAPK14 1615/4885 |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, MAP3K5, MAPKAPK5 | THRB 3971/4885DHODH 972/4885MAPK14 70/4885 |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | THRB 3487/4885DHODH 177/4885MAPK14 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.